SCHEMBL6500712

SCHEMBL6500712

Cc1nc2ccc(C(=O)O)nc2n1Cc1ccc(NC(=O)OC(C)C)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 5/20 0.42
HTT P42858 4/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
LMNA P02545 4/20 0.41
NPC1 O15118 1/20 0.41
AGPAT2 O15120 1/20 0.41
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
GAA P10253 2/20 0.38
PPARG P37231 1/20 0.38
PTGDR2 Q9Y5Y4 3/20 0.38
PTGES O14684 1/20 0.38
AGTR1 P30556 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502802 0.92 SMN1; SMN2 (0.43) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6491394 0.89 ALDH1A1 (0.49) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6497514 0.87 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6298711 0.87 SMN1; SMN2 (0.54) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6491426 0.86 SMN1; SMN2 (0.36) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6301313 0.85 PTGDR2 (0.52) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6305837 0.85 MAPT (0.53) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6298617 0.84 KMT2A (0.44) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6492824 0.84 PPARG (0.51) ALDH1A1MAPTSMN1; SMN2KDM4EHTT
SCHEMBL6491902 0.83 PPARG (0.54) ALDH1A1MAPTSMN1; SMN2KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A ALDH1A1 476/4885MAPT 4144/4885SMN1; SMN2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.